Eirini Vasarmidi
Overview
Explore the profile of Eirini Vasarmidi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otaola M, Maria O, Vasarmidi E, Eirini V, Sebastien O, Ottaviani S, et al.
Chest
. 2024 Dec;
PMID: 39675519
Background: The screening strategy for interstitial lung disease (ILD) in patients with rheumatoid arthritis is currently debated. Although high-resolution CT (HRCT) imaging is the gold standard for diagnosing ILD, its...
2.
Ghanem M, Archer G, Justet A, Jaillet M, Vasarmidi E, Mordant P, et al.
Am J Respir Crit Care Med
. 2024 Dec;
211(3):486-498.
PMID: 39637324
Idiopathic pulmonary fibrosis (IPF) is a lethal disease with limited therapeutic options. FGF21 (fibroblast growth factor 21), an endocrine fibroblast growth factor that acts through the FGFR1 (fibroblast growth factor...
3.
Bouloukaki I, Michelakis S, Tsitoura E, Vasarmidi E, Koutoulaki C, Tzanakis N, et al.
Exp Ther Med
. 2024 Dec;
29(1):16.
PMID: 39624594
Obstructive sleep apnea (OSA) and idiopathic pulmonary fibrosis (IPF) frequently coexist. Elevated levels of Krebs von den Lungen-6 (KL-6), endothelin-1 (ET-1) and S100 calcium-binding protein A9 (S100A9) have been observed...
4.
Ghanem M, Justet A, Jaillet M, Vasarmidi E, Boghanim T, Hachem M, et al.
Am J Physiol Lung Cell Mol Physiol
. 2024 Oct;
327(6):L818-L830.
PMID: 39350729
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic options. Fibroblast growth factor receptor-4 (FGFR4) is a known receptor for several paracrine fibroblast growth factors (FGFs). FGFR4...
5.
Vasarmidi E, Lambiri I, Foteinaki E, Stamatopoulou V, Mitrouska I, Pitsidianakis G, et al.
Breathe (Sheff)
. 2024 Aug;
20(2):240029.
PMID: 39206278
https://bit.ly/4bTP8fJ.
6.
Juge P, Sparks J, Gazal S, Ebstein E, Borie R, Debray M, et al.
Rheumatol Adv Pract
. 2024 Jun;
8(2):rkae059.
PMID: 38854416
Objective: Recently, a genome-wide association study identified an association between RA-associated interstitial lung disease (ILD) and rs12702634 in the Japanese population, especially for patients with a usual interstitial pneumonia (UIP)...
7.
Matthaiou A, Bizymi N, Pagonidis K, Manousaki E, Fragkoulakis M, Lambiri I, et al.
J Pers Med
. 2024 Feb;
14(2).
PMID: 38392595
Coronavirus disease 2019 (COVID-19) pneumonia is associated with extensive pulmonary microangiopathy and the enlargement of the pulmonary artery (PA), while its progression after the remission of the disease has not...
8.
Calaras D, David A, Vasarmidi E, Antoniou K, Corlateanu A
Can Respir J
. 2024 Jan;
2024:4919951.
PMID: 38283656
Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease caused by chronic inhalation of a wide variety of antigens in susceptible and sensitized individuals, commonly associated with an occupational exposure....
9.
Symvoulakis E, Vasarmidi E, Linardakis M, Tsiavos A, Mantadaki A, Pitsidianakis G, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2023 Jun;
40(2):e2023022.
PMID: 37382071
Background: In Primary Health Care (PHC) many interstitial lung disease (ILD) cases may remain at diagnostic delay, due to their challenging presentation and the limited experience of general practitioners (GPs)...
10.
Karampitsakos T, Tzilas V, Papaioannou O, Chrysikos S, Vasarmidi E, Juge P, et al.
Front Med (Lausanne)
. 2023 Jan;
9:1096203.
PMID: 36698813
Introduction: Myositis associated interstitial lung disease (ILD) seems to be an under-recognized entity. Methods: In this multicenter, retrospective study, we recorded between 9/12/2019 and 30/9/2021 consecutive patients who presented in...